Press Releases

A unique two-drug immunotherapy combination first evaluated at Roswell Park as an approach for treating some cancers will soon be available to cancer patients with COVID-19. The U.S. Food and Drug Administration has authorized a study assessing the safety and effectiveness of giving both rintatolimod and interferon alfa to cancer patients with COVID-19.

Providing the best care and services for cancer patients requires careful integration of key teams across many different disciplines and programs. The appointment of new leaders in three key areas of clinical care at Roswell Park Comprehensive Cancer Center highlights the breadth of services and extent of expertise available to patients and their families.

New research led by a pediatric oncology expert from Roswell Park Comprehensive Cancer Center underscores that diets high in antioxidant-rich foods can have particular benefits for young cancer patients. Published in the Journal of Clinical Oncology, the cohort study involved more than 500 pediatric patients with acute lymphoblastic leukemia (ALL).

Aggressive forms of prostate cancer don’t act the way they should, hanging on to genetic materials called introns that should be thrown away, a new six-year study led by Dean Tang, PhD, and Song Liu, PhD, of Roswell Park Comprehensive Cancer Center has revealed.

The latest resources from Roswell Park Comprehensive Cancer Center related to the COVID-19 pandemic offers information for patients, medical professionals and the general public.

Four recent published studies highlight important research by Roswell Park Comprehensive Cancer Center scientists in several types of cancers. They range from new insights on effective treatment decision-making for patients with rectal cancer to new strategies for improving outcomes or reducing side effects for patients with prostate cancer, pancreatic cancer and melanoma.

Western New York healthcare and medical research leaders are joining forces in an effort to uncover hidden information from the cells of those who have been exposed to the novel coronavirus, seeking insights on how best to care for those who develop COVID-19 illness.

A new analysis led by physicians at Roswell Park Comprehensive Cancer Center, published in JAMA Network Open, shows that some patients with small node-negative breast tumors that test positive for both the hormone receptor (HR) and ERBB2, also known as HER2/neu, proteins could benefit from chemotherapy in addition to surgery, radiation and endocrine therapy.

While it has long been thought that locally-delivered radiation therapy typically does not help to shrink tumors outside the field of irradiation, new preclinical research from a team at Roswell Park Comprehensive Cancer Center suggests a strategy for significantly increasing both the local and distant, or “abscopal,” effects of radiation.